Acumen Pharmaceuticals, Inc. (ABOS)

US — Healthcare Sector
Peers: TERN  XFOR  DAWN  HOOK  AMLX  INZY  MREO 

Automate Your Wheel Strategy on ABOS

With Tiblio's Option Bot, you can configure your own wheel strategy including ABOS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ABOS
  • Rev/Share 0.0029
  • Book/Share 1.9328
  • PB 0.7269
  • Debt/Equity 0.2552
  • CurrentRatio 5.9693
  • ROIC -0.9792

 

  • MktCap 85105627.0
  • FreeCF/Share -1.9456
  • PFCF -0.7221
  • PE -0.6227
  • Debt/Assets 0.1738
  • DivYield 0
  • ROE -0.8139

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ABOS Citigroup -- Buy -- $4 June 17, 2025

News

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
ABOS
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.

Read More
image for news Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript
ABOS
Published: August 12, 2025 by: Seeking Alpha
Sentiment: Neutral

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Director Eric Siemers - Chief Medical Officer James Doherty - President & Chief Development Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Jason Eron Zemansky - BofA Securities, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Pete George Stavropoulos - Cantor Fitzgerald & Co., Research Division Trung Chuong Huynh - UBS Investment Bank, Research Division Operator Good day, and …

Read More
image for news Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
ABOS
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and CBO Dr. Jim Doherty - President and CDO Dr. Eric Siemers - Chief Medical Officer Conference Call Participants Sarah Medeiros - Cantor Fitzgerald Tom Shrader - BTIG Ting Liu - UBS Operator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 Conference Call and Webcast.

Read More
image for news Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript

About Acumen Pharmaceuticals, Inc. (ABOS)

  • IPO Date 2021-07-01
  • Website https://acumenpharm.com
  • Industry Biotechnology
  • CEO Daniel J. O'Connell
  • Employees 61
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.